{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05067556",
            "orgStudyIdInfo": {
                "id": "MCC-21-18366"
            },
            "organization": {
                "fullName": "Virginia Commonwealth University",
                "class": "OTHER"
            },
            "briefTitle": "Decreasing Long-term Opioid Use in Cancer Survivors",
            "officialTitle": "Creating a Pathway for Disease-Free Cancer Survivors to Decrease Long-term Opioid Use",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "decreasing-long-term-opioid-use-in-cancer-survivors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-12-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-03-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-03-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-16",
            "studyFirstSubmitQcDate": "2021-10-04",
            "studyFirstPostDateStruct": {
                "date": "2021-10-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Virginia Commonwealth University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a feasibility pilot trial assessing a behavioral intervention for chronic pain among disease-free cancer survivors to decrease long-term opioid dependence.",
            "detailedDescription": "To assess the feasibility and acceptability of implementing brief Acceptance and Commitment Therapy for chronic pain (ACT-CP) in a Survivorship clinic."
        },
        "conditionsModule": {
            "conditions": [
                "Pain",
                "Chronic Pain",
                "Cancer Pain",
                "Survivorship"
            ],
            "keywords": [
                "Commitment Therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intervention",
                    "type": "EXPERIMENTAL",
                    "description": "Acceptance and Commitment Therapy for Chronic Pain (ACT-CP)",
                    "interventionNames": [
                        "Behavioral: Acceptance and Commitment Therapy for chronic pain (ACT-CP)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Acceptance and Commitment Therapy for chronic pain (ACT-CP)",
                    "description": "Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.",
                    "armGroupLabels": [
                        "Intervention"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Recruitment yield of participants contacted",
                    "description": "Study feasibility will be assessed by tracking the number of patients contacted",
                    "timeFrame": "12 Months"
                },
                {
                    "measure": "Recruitment yield of participants consented",
                    "description": "Study feasibility will be assessed by tracking the number of participants that consent to enroll in the trial.",
                    "timeFrame": "12 Months"
                },
                {
                    "measure": "Recruitment yield number of participants enrolled",
                    "description": "Study feasibility will be assessed by recruitment yield, i.e., tracking the number of participants who initiated treatment.",
                    "timeFrame": "12 Months"
                },
                {
                    "measure": "Session Attendance",
                    "description": "Study feasibility will be assessed by tracking the number of participants attend each intervention session over the course of the 6-week intervention period.",
                    "timeFrame": "6 Weeks"
                },
                {
                    "measure": "Participant Satisfaction",
                    "description": "Study acceptability will be assessed by administering a post-intervention satisfaction survey which asks about satisfaction with the program including perceived efficacy and suggestions for improvement.",
                    "timeFrame": "6 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pain Intensity",
                    "description": "Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by analyzing change in self-reported pain scores using The Patient-Reported Outcome Measurement Information System short form 3a v1.0 (PROMIS). This tool measures how much a person hurts.",
                    "timeFrame": "6 Weeks"
                },
                {
                    "measure": "Opioid Use Frequency",
                    "description": "Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by self-reported opioid use frequency weekly throughout the intervention period.",
                    "timeFrame": "6 Weeks"
                },
                {
                    "measure": "Pain interference",
                    "description": "Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by analyzing pain interference using the PROMIS short form 8a. The PROMIS Pain Interference instrument measures the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.",
                    "timeFrame": "6 Weeks"
                },
                {
                    "measure": "Opioid Refill Frequency",
                    "description": "Frequency of opioid refills will be assessed via pharmacy records available in patients' EMR",
                    "timeFrame": "6 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of cancer of any type, currently in remission, having completed active primary therapy. Patients on oral adjuvant hormone therapy will still be eligible.\n* Completed active therapy must have been curative in intent (for example stage IV cancer patients such as head and neck cancer patients treated with curative intent are eligible).\n* Self-reported cancer pain for \\>= 3 months\n* Opioid use \\>= 5MME/day (morphine milligram equivalents) as prescribed by physician for cancer-related pain for at least 6 months beyond completion of their cancer treatment\n* VCUHealth system patient\n\nExclusion Criteria:\n\n* History of opioid use prior to cancer diagnosis\n* Anyone with prior history of substance use disorder or currently enrolled in a methadone program\n* Anyone with schizophrenia or bipolar disorder\n* Current utilization of psychotherapy services for pain, depression, anxiety, and/or PTSD\n* Cognitive concerns that would prevent meaningful engagement in treatment\n* Inability to converse in English\n* Lack of working telephone and Internet connection (must have at least one or the other)\n* Anyone found to have progression of cancer\n* Anyone diagnosed with cancer recurrence or new cancer during their study period\n* Documented diagnosis of or positive screen for current substance use disorder (score \\>5 on the Drug Abuse Screening Test-10 \\[DAST-10\\])\n* Anyone scoring \\>=8 on ORT indicating very high risk for opioid abuse",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Autumn Lanoye, PhD",
                    "role": "CONTACT",
                    "phone": "804-828-4929",
                    "email": "autumn.lanoye@vcuhealth.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Susan Hong, MD, MPH",
                    "affiliation": "Virginia Commonwealth University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Virginia Commonwealth University",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23219",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Autumn Lanoye, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "There is no plan to share individual participant data at this time"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000059350",
                    "term": "Chronic Pain"
                },
                {
                    "id": "D000072716",
                    "term": "Cancer Pain"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M29442",
                    "name": "Chronic Pain",
                    "asFound": "Chronic Pain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M1091",
                    "name": "Cancer Pain",
                    "asFound": "Cancer Pain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}